Baseline characteristics and long-term outcomes of steroid-resistant nephrotic syndrome in children: impact of initial kidney histology

被引:4
作者
Watanabe, Yoshitaka [1 ,2 ]
Fujinaga, Shuichiro [1 ]
Endo, Amane [3 ]
Endo, Shota [1 ]
Nakagawa, Mayu [1 ]
Sakuraya, Koji [1 ]
机构
[1] Saitama Childrens Med Ctr, Div Nephrol, Chuo Ku, 1-2 Shintoshin, Saitama, Saitama 3308777, Japan
[2] Showa Univ, Childrens Med Ctr, Northern Yokohama Hosp, Yokohama, Kanagawa, Japan
[3] Juntendo Univ, Dept Pediat & Adolescent Med, Tokyo, Japan
关键词
Initial steroid-resistant nephrotic syndrome; Immune-based etiology; Focal segmental glomerulosclerosis; Minimal change disease; Single disease spectrum; Children; SELECTIVITY; PROTEINURIA; DISEASE;
D O I
10.1007/s00467-020-04760-8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Although many pediatric nephrologists consider focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) as separate clinical entities, whether the initial histology could affect clinical courses in children with steroid-resistant nephrotic syndrome (SRNS) suspected of having an immune-based etiology remains unknown, especially for long-term outcomes. Methods We retrospectively reviewed long-term outcomes (> 3 years; median follow-up, 9.1 years) of 21 children with initial SRNS (FSGS,N = 9; MCD,N = 12) who achieved complete remission with immunosuppressive agents, including cyclosporine. Results At NS onset, incidence of acute kidney injury (67% vs. 8%,P < 0.05) and proportion of patients with non-selective proteinuria (56% vs. 0%,P < 0.01) were significantly higher in the FSGS group than the MCD group. Furthermore, median days until complete remission after treatment was significantly longer in the FSGS group than the MCD group (116 days vs. 45 days,P < 0.001). Although subsequent biopsy histology of the 12 patients in the MCD group was still identical in all MCD, three of nine patients in the FSGS group were reclassified from FSGS to MCD at second biopsy. At last visit, all patients maintained complete remission, and none developed chronic kidney disease. Conclusions Initial presentation in the FSGS group was characterized by more severe clinical manifestations than the MCD group. If complete remission is achieved, FSGS and MCD in children with immune-mediated SRNS may constitute a single disease spectrum because the long-term outcomes are favorable, irrespective of initial histology.
引用
收藏
页码:2377 / 2381
页数:5
相关论文
共 50 条
  • [41] IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome
    Trautmann, Agnes
    Vivarelli, Marina
    Samuel, Susan
    Gipson, Debbie
    Sinha, Aditi
    Schaefer, Franz
    Hui, Ng Kar
    Boyer, Olivia
    Saleem, Moin A.
    Feltran, Luciana
    Mueller-Deile, Janina
    Becker, Jan Ulrich
    Cano, Francisco
    Xu, Hong
    Lim, Yam Ngo
    Smoyer, William
    Anochie, Ifeoma
    Nakanishi, Koichi
    Hodson, Elisabeth
    Haffner, Dieter
    PEDIATRIC NEPHROLOGY, 2020, 35 (08) : 1529 - 1561
  • [42] Risk factors and renal outcomes of AKI in children with secondary steroid-resistant nephrotic syndrome
    Yu, Nannan
    Ouyang, Xiaojun
    Li, Jie
    Gao, Jie
    Zeng, Shuhan
    Zhuang, Hongjie
    Jiang, Mengjie
    Pei, Yuxin
    Jiang, Xiaoyun
    RENAL FAILURE, 2024, 46 (01)
  • [43] Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome
    Zhuwen Yi
    Zhihui Li
    Xiao-Chuan Wu
    Qing-Nan He
    Xi-Qiang Dang
    Xiao-Jie He
    Pediatric Nephrology, 2006, 21 : 967 - 972
  • [44] Novel mutation patterns in children with steroid-resistant nephrotic syndrome
    Prasad, Narayan
    Meyyappan, Jeyakumar
    Dhanorkar, Manoj
    Kushwaha, Ravi
    Mandal, Kausik
    Veeranki, Vamsidhar
    Behera, Manas
    Patel, Manas
    Yadav, Brijesh
    Bhadauria, Dharmendra
    Kaul, Anupama
    Yaccha, Monika
    Bhatt, Mansi
    Agarwal, Vinita
    Jain, Monoj
    CLINICAL KIDNEY JOURNAL, 2024, 17 (08)
  • [45] Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome
    Yi, Zhuwen
    Li, Zhihui
    Wu, Xiao-Chuan
    He, Qing-Nan
    Dang, Xi-Qiang
    He, Xiao-Jie
    PEDIATRIC NEPHROLOGY, 2006, 21 (07) : 967 - 972
  • [46] Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children
    Kamei, Koichi
    Ishikura, Kenji
    Sako, Mayumi
    Ito, Shuichi
    Nozu, Kandai
    Iijima, Kazumoto
    PEDIATRIC NEPHROLOGY, 2020, 35 (01) : 17 - 24
  • [47] Screening for urinary biomarkers of steroid-resistant nephrotic syndrome in children
    Bai, Yongqi
    Liu, Wenjun
    Guo, Qulian
    Zou, Yan
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (03) : 860 - 864
  • [48] Current understandings in treating children with steroid-resistant nephrotic syndrome
    Jiwon M. Lee
    Andreas Kronbichler
    Jae Il Shin
    Jun Oh
    Pediatric Nephrology, 2021, 36 : 747 - 761
  • [49] Genetic mutation in Egyptian children with steroid-resistant nephrotic syndrome
    Thomas, Manal Micheal
    Abdel-Hamid, Mohamed S.
    Mahfouz, Nermine Nabil
    Ghobrial, Emad Emil
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (01) : 48 - 53
  • [50] IPNA consensus definitions for clinical trial outcomes in steroid-resistant nephrotic syndrome
    Hari, Pankaj
    Khandelwal, Priyanka
    Boyer, Olivia
    Bhimma, Rajendra
    Cano, Francesco
    Christian, Martin
    Duzova, Ali
    Iijima, Kazumoto
    Kang, Hee
    Qian, Shen
    Safouh, Hesham
    Samuels, Susan
    Smoyer, William
    Vivarelli, Marina
    Bagga, Arvind
    Schaefer, Franz
    PEDIATRIC NEPHROLOGY, 2025, 40 (03) : 865 - 872